Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase I trial aims to investigate the safety and tolerability of low dose
radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in
combination with programmed cell death-1 (PD-1) inhibitors in Stage IV non-small cell lung
cancer (NSCLC) patients who have failed standard therapy. At least 14 participants will be
enrolled in this study. All will take part at West China Hospital, Sichuan University.